The European Commission will weigh the positive recommendation by the Committee for Medicinal Products for Human Use, or CHMP, as it considers whether Harvoni - a combination of Gilead's Sovaldi and its experimental drug ledipasvir - can be sold in 28 European countries. The move comes as the Food and Drug Administration ways approval of the drug, which Foster City-based Gilead has hinted could cost under $100,000 .